Skip to content

Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery

Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery - Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031984
Enrollment
30
Registered
2018-03-30
Start date
2017-03-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Interventions

Subjects take a new Investigational new food &quot
Impact&quot
of 125 ml / 1 pack 4 packs a day from 6 days before the scheduled operation date to 2 days before the scheduled operation date.

Sponsors

Juntendo university Department of Coloproctological Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Cases diagnosed as histologically colon cancer. 2. Cases who intestinal resection is scheduled. 3. Cases who can eat by oral ingestion. 4. After receiving sufficient explanation for participation in the research, cases that written consent was obtained.

Exclusion criteria

Exclusion criteria: 1. Cases with intestinal obstruction and high intestinal stenosis. 2. Duplicated cancer cases. 3. Cases with heart dysfunction, liver dysfunction, and kidney dysfunction. 4. Cases who are prescribed prednisolone 6 mg / day cases of steroid. 5. Pregnant women, breast-feeding cases, and cases that may be pregnant. 6. Cases who are observed clear infection foci before registration. 7. Cases after total gastrectomy. 8. Cases with Parkinson's disease; Hoehn and Yahr scale 3 or more. 9. Cases who are prescribed immunosuppressive drugs. 10. Cases with milk allergy and/or soybeans allergy. 11. Case having diabetes with HbA1c 7.0 or higher. 12. Cases considered inappropriate by researchers.

Design outcomes

Primary

MeasureTime frame
Surgical site infection (SSI) such as wound infection and intraperitoneal abscess. Infectious diseases other than SSI such as respiratory infections and urinary tract infections. Incidence of suture failure.

Countries

Japan

Contacts

Public ContactToshiaki Hagiwara

Juntendo university Department of Coloproctological Surgery

thagiwa@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026